Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States

Abstract Background Preference valuations of health status are essential in health technology and economic appraisal. This study estimated utilities for treatment-related health states of acute myeloid leukemia (AML) and disutilities of severe adverse events (SAEs) using a representative sample of a...

Full description

Bibliographic Details
Main Authors: Eytan M. Stein, Min Yang, Annie Guerin, Wei Gao, Philip Galebach, Cheryl Q. Xiang, Subrata Bhattacharyya, Gaetano Bonifacio, George J. Joseph
Format: Article
Language:English
Published: BMC 2018-09-01
Series:Health and Quality of Life Outcomes
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12955-018-1013-9
_version_ 1819262000694296576
author Eytan M. Stein
Min Yang
Annie Guerin
Wei Gao
Philip Galebach
Cheryl Q. Xiang
Subrata Bhattacharyya
Gaetano Bonifacio
George J. Joseph
author_facet Eytan M. Stein
Min Yang
Annie Guerin
Wei Gao
Philip Galebach
Cheryl Q. Xiang
Subrata Bhattacharyya
Gaetano Bonifacio
George J. Joseph
author_sort Eytan M. Stein
collection DOAJ
description Abstract Background Preference valuations of health status are essential in health technology and economic appraisal. This study estimated utilities for treatment-related health states of acute myeloid leukemia (AML) and disutilities of severe adverse events (SAEs) using a representative sample of adults from the general population in the United States (US). Methods Treatment-related AML health states, defined based on literature and interviews with clinicians, included complete remission (CR), no CR, relapse, stem cell transplant (SCT), and post SCT short-term recovery. Six attributes with varying levels, including fever, lack of energy, problems with daily function, anxiety/depression, blood transfusions, and hospitalization, were used to define health states. An online survey using discrete choice experiment methodology was designed to capture preferences for health status scenarios including the identified attributes and key grade 3/4 chemotherapy-related SAEs. Health state utilities and SAE disutilities were generated from a conditional logistic regression with generalized estimating equations. Results Of the 300 survey participants, the demographic distributions were within a 3% margin of those in the 2010 US Census. CR had the highest utility value (0.875), followed by post-SCT short-term recovery (0.398), relapse (0.355), no CR (0.262), and SCT (0.158). Of the SAEs, serious infection had the highest decline in utility (0.218), followed by severe diarrhea (0.176), abnormally low blood cell counts (0.100), and severe redness/skin peeling (0.060). Conclusions AML and treatments can result in reduced quality of life and impaired ability to perform daily activities. Findings of this study underline the value that society places on treatment-related AML health states and SAEs.
first_indexed 2024-12-23T19:50:44Z
format Article
id doaj.art-d237ba30b31c4c1a8cd41e5c026b90bd
institution Directory Open Access Journal
issn 1477-7525
language English
last_indexed 2024-12-23T19:50:44Z
publishDate 2018-09-01
publisher BMC
record_format Article
series Health and Quality of Life Outcomes
spelling doaj.art-d237ba30b31c4c1a8cd41e5c026b90bd2022-12-21T17:33:24ZengBMCHealth and Quality of Life Outcomes1477-75252018-09-0116111210.1186/s12955-018-1013-9Assessing utility values for treatment-related health states of acute myeloid leukemia in the United StatesEytan M. Stein0Min Yang1Annie Guerin2Wei Gao3Philip Galebach4Cheryl Q. Xiang5Subrata Bhattacharyya6Gaetano Bonifacio7George J. Joseph8Memorial Sloan Kettering Cancer CenterAnalysis Group, IncAnalysis Group, IncAnalysis Group, IncAnalysis Group, IncAnalysis Group, IncNovartis Healthcare Pvt, LtdNovartis Pharmaceuticals CorporationNovartis Pharmaceuticals CorporationAbstract Background Preference valuations of health status are essential in health technology and economic appraisal. This study estimated utilities for treatment-related health states of acute myeloid leukemia (AML) and disutilities of severe adverse events (SAEs) using a representative sample of adults from the general population in the United States (US). Methods Treatment-related AML health states, defined based on literature and interviews with clinicians, included complete remission (CR), no CR, relapse, stem cell transplant (SCT), and post SCT short-term recovery. Six attributes with varying levels, including fever, lack of energy, problems with daily function, anxiety/depression, blood transfusions, and hospitalization, were used to define health states. An online survey using discrete choice experiment methodology was designed to capture preferences for health status scenarios including the identified attributes and key grade 3/4 chemotherapy-related SAEs. Health state utilities and SAE disutilities were generated from a conditional logistic regression with generalized estimating equations. Results Of the 300 survey participants, the demographic distributions were within a 3% margin of those in the 2010 US Census. CR had the highest utility value (0.875), followed by post-SCT short-term recovery (0.398), relapse (0.355), no CR (0.262), and SCT (0.158). Of the SAEs, serious infection had the highest decline in utility (0.218), followed by severe diarrhea (0.176), abnormally low blood cell counts (0.100), and severe redness/skin peeling (0.060). Conclusions AML and treatments can result in reduced quality of life and impaired ability to perform daily activities. Findings of this study underline the value that society places on treatment-related AML health states and SAEs.http://link.springer.com/article/10.1186/s12955-018-1013-9Acute myeloid leukemiaDiscrete choice experimentHealth statePreference valuationUtility
spellingShingle Eytan M. Stein
Min Yang
Annie Guerin
Wei Gao
Philip Galebach
Cheryl Q. Xiang
Subrata Bhattacharyya
Gaetano Bonifacio
George J. Joseph
Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States
Health and Quality of Life Outcomes
Acute myeloid leukemia
Discrete choice experiment
Health state
Preference valuation
Utility
title Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States
title_full Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States
title_fullStr Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States
title_full_unstemmed Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States
title_short Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States
title_sort assessing utility values for treatment related health states of acute myeloid leukemia in the united states
topic Acute myeloid leukemia
Discrete choice experiment
Health state
Preference valuation
Utility
url http://link.springer.com/article/10.1186/s12955-018-1013-9
work_keys_str_mv AT eytanmstein assessingutilityvaluesfortreatmentrelatedhealthstatesofacutemyeloidleukemiaintheunitedstates
AT minyang assessingutilityvaluesfortreatmentrelatedhealthstatesofacutemyeloidleukemiaintheunitedstates
AT annieguerin assessingutilityvaluesfortreatmentrelatedhealthstatesofacutemyeloidleukemiaintheunitedstates
AT weigao assessingutilityvaluesfortreatmentrelatedhealthstatesofacutemyeloidleukemiaintheunitedstates
AT philipgalebach assessingutilityvaluesfortreatmentrelatedhealthstatesofacutemyeloidleukemiaintheunitedstates
AT cherylqxiang assessingutilityvaluesfortreatmentrelatedhealthstatesofacutemyeloidleukemiaintheunitedstates
AT subratabhattacharyya assessingutilityvaluesfortreatmentrelatedhealthstatesofacutemyeloidleukemiaintheunitedstates
AT gaetanobonifacio assessingutilityvaluesfortreatmentrelatedhealthstatesofacutemyeloidleukemiaintheunitedstates
AT georgejjoseph assessingutilityvaluesfortreatmentrelatedhealthstatesofacutemyeloidleukemiaintheunitedstates